Striant Articles
ProStrakan to sell Cellegy drugs in CIS/Russia
3 July 2006
Melbourn Sci expands dissolution testing
19 June 2006
US FDA approves Alza's IONSYS
29 May 2006
Vivus' Evamist sees strong Ph III data
15 May 2006
Shire's net income improves 75% in 1st qtr
8 May 2006
Schwarz's 1st-qtr sales up 4% to 274M euros
8 May 2006
FDA accepts Antares' Bio-E-Gel NDA
1 May 2006
AEterna's Cetrotide cleared for IVF in Japan
1 May 2006
J&J's 1st-qtr 2006 earnings up 16.4%, but sales weak
24 April 2006
Noven's Daytrana gets FDA go-ahead for ADHD
17 April 2006
Ardana's testosterone cream sees good Ph II data
17 April 2006
Degralix shows promise for prostate cancer
17 April 2006
GSK's ReQuip fares well vs Schwarz' Neupro
17 April 2006
Schwarz' Neupro launched in the UK
10 April 2006
Schwarz' Neupro launched in the UK
10 April 2006
Solvay signs AndroGel expansion deal
27 March 2006
Bentley reports 33% increase in revenue
20 March 2006
Celtic licenses IDEA's Transfersome
27 February 2006
Acadia announces advances in two key R&D programs
27 February 2006
Solvay's 2005 revenue reaches 8.5 B euros
27 February 2006
Mylan Labs promotes Carolyn Myers
20 February 2006
ProStraken provides update on Sancuso and Tostrex trials
13 February 2006
Mylan sees solid third-quarter results
13 February 2006
Ardana's testosterone cream on track for Ph III
6 February 2006
Ionsys gains EU marketing go-ahead
6 February 2006
J&J's 4th-qtr 2005 sales drop 1.1% on low Rx
30 January 2006
Zonagen gets IRB appro for Ph III Androxal trial
16 January 2006
Schering AG's osteoperosis patch gets US go ahead
9 January 2006
Savient to sell Delatestryl to Indevus
19 December 2005
Consumer interest in drug delivery can raise compliance; study
19 December 2005
Noven to start making Daytrana
19 December 2005
FDA: Shire's Daytrana safe and effective
12 December 2005
ALZA resubmits NDA for Ionsys
5 December 2005
Ardana's Teverelix on track for FDA IND
12 September 2005
GTx reveals positive trial results for Ostarine
12 September 2005
Altea completes Ph II trials of pain management patch
12 September 2005
Spectrum's Ozarelix Ph II trial due to begin
5 September 2005
BioSante licenses contraceptive tech from Wake Forest Univ
15 August 2005
US FDA posts DSOB meeting summary
15 August 2005
Scotland OKs Xeloda but fears in England/Wales
15 August 2005
Shire and Noven resubmit MTS for pediatric ADHD
1 August 2005
Cytochemia to market Striant in Germany
27 June 2005
Mylan sees 12% drop in fourth-qtr profit
23 May 2005
MacroChem: Opterone is proven bioavailable
23 May 2005
Ardana's Teverelix sees positive PhII results
23 May 2005
Shire provides key R&D candidates update
16 May 2005
France's Ipsen sees 8.6% sales growth
16 May 2005
First launch for UCB's Kentera for OAB
25 April 2005
Spectrum starts Ph II SPI-153 cancer trial
18 April 2005
BioSante's Bio-E-Gel completes Phase III
18 April 2005
Positive data for Shire/Noven's ADHD drug
18 April 2005
Antares unveils contraceptive transdermal gel
11 April 2005
Watson's Trelstar is launched in USA
11 April 2005
KSL and Kagoshima Univ give transdermal delivery a boost
11 April 2005
Janssen launches Durogesic
7 March 2005
Encouraging data for Ardana's Teverelix
28 February 2005
Amarin wins domestic approval for Fentanyl TDS
28 February 2005
Vivus' testosterone spray for women with sexual desire disorder?
28 February 2005
Watson Pharma's EPS tops analysts' hopes
21 February 2005
Mylan's 3rd-qtr revenues slump 17%
14 February 2005
ICOS and Solvay form AndroGel alliance
7 February 2005
J&J's 4th-qtr net earnings plunge 34%
31 January 2005
New product launches in 2004
31 January 2005
LAM Pharma to buy Chinese drug firm in $14M deal
17 January 2005
Tostrex granted first EU clearance in Sweden
10 January 2005
Theratechnologies sells share in Macroflux projects to Alza
10 January 2005
B-MS and Somerset in Emsam distribution deal
10 January 2005
Endo Pharma issues 2005 guidance
10 January 2005
Acrux grants CSL Fentanyl rights
10 January 2005
Auxilium/Ipsen's Testim OKed in EU
20 December 2004
Par buys 5% of Abrika and signs generics deal
13 December 2004
Stock Commentary - New York
13 December 2004
P&G's Intrinsa rejected by FDA panel
13 December 2004
Novavax reaffirms clinical strategy for Androsorb
13 December 2004
Vivus completes Ph II study for HSDD drug
22 November 2004
$10B transdermal/ transmucosal Rx delivery market by 2010: study
22 November 2004
Bentley's revenues jump 21% for 3rd qtr
15 November 2004
EU's MRP completed for Columbia's Striant
1 November 2004
EpiTan focuses on Melanotan, a potential blockbuster
1 November 2004
Mylan lowers 2nd-qtr earnings forecast
25 October 2004
Tokyo pharma stocks - week to October 4
11 October 2004
Transdermal-delivery market to reach $16.3B by 2007
11 October 2004
Global analgesic mkt "to nearly double by 2010"
4 October 2004
P&G's Intrinsa gets FDA priority review
27 September 2004
Mylan to appeal fentanyl ruling
23 August 2004
Bentley's 2nd-qtr sales jump to all time high
9 August 2004
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
